{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:19:57Z","timestamp":1778642397648,"version":"3.51.4"},"reference-count":16,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2021,4,8]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background\/aims<\/jats:title>\n                  <jats:p>OASIS is a Phase IIIb trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01429441\">NCT01429441<\/jats:ext-link>) assessing long-term outcomes in subjects with symptomatic vitreomacular adhesion (VMA). The purpose of this study is to report on the frequency, severity, location and time course of ellipsoid zone (EZ) alterations in ocriplasmin-treated and sham control eyes in the OASIS study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>220 patients (146 ocriplasmin, 74 sham) subjects with VMA were enrolled in this masked post hoc analysis phase IIIb, randomised, sham-controlled double-masked multicentre clinical trial. A masked post hoc analysis of OCT images was performed at the Doheny Image Reading Center from subjects enrolled in the OASIS trial. The status of the EZ band was assessed in three different macular regions: the central subfield (CS) (\u22641\u2009mm diameter), the parafoveal area (PAA) (&gt;1 to \u22643\u2009mm) and the perifoveal area (PEA) (&gt;3 to \u22646\u2009mm). The EZ band was rated as normal\/intact, full thickness macular hole (FTMH), abnormal but continuous, discontinuous\/disrupted or absent at visits from baseline (pretreatment) to week 1 (day 7), month 1 (day 28), month 3, month 6, month 12 and the final follow-up at month 24. EZ band status was compared in both study and control eyes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 208 patients (138 ocriplasmin, 70 sham) were included in this analysis. At baseline, FTMH was present in 48.6%, 8.0%, 0% and 52.8%, 2.9%, 0% in the CS, PAA and PEA of the ocriplasmin and sham groups, respectively. The EZ was graded to be abnormal but continuous, discontinuous\/disrupted or absent at Baseline in 21.0%, 4.3%, 2.8% in the CS, PAA and PEA, respectively, of the ocriplasmin group; and 12.9%, 10.0%, 4.3% in the CS, PAA and PEA of the sham group. For the ocriplasmin group in the PAA, this frequency increased to 6.6% at week 1, was 9.8% at month 1, but improved to 3.8% at month 3, and remained stable to 1.6% at month 24. These differences, however, were not statistically significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ocriplasmin treatment for symptomatic VMA was associated with EZ abnormalities in a small percentage of patients that was best assessed in regions (PEA) relatively unaffected by the VM interface disease at baseline. The EZ abnormalities were apparent by week 1, persisted at month 1, and appeared to resolve in the majority of cases by month 3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01429441\">NCT01429441<\/jats:ext-link>\n                  <\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2020-000648","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T12:20:20Z","timestamp":1624278020000},"page":"e000648","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Post hoc analysis of ellipsoid zone changes beyond the central subfield in symptomatic vitreomacular adhesion patients from the OASIS trial"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01429441","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01429441","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01429441","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Swetha Bindu","family":"Velaga","sequence":"first","affiliation":[{"name":"Retina, Doheny Eye Institute, Los angeles, California, USA"},{"name":"Ophthalmology, Doheny Eye Institute, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3802-6594","authenticated-orcid":false,"given":"Muneeswar Gupta","family":"Nittala","sequence":"additional","affiliation":[{"name":"Ophthalmology, Doheny Eye Institute, University of California Los Angeles, Los Angeles, California, USA"},{"name":"Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S","family":"Ip","sequence":"additional","affiliation":[{"name":"Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Duchateau","sequence":"additional","affiliation":[{"name":"Biometrics Research Centre, Ghent University, Gent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-8051","authenticated-orcid":false,"given":"SriniVas R","family":"Sadda","sequence":"additional","affiliation":[{"name":"Retina, Doheny Eye Institute, Los angeles, California, USA"},{"name":"Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Pasadena, California, USA"},{"name":"Ophthalmology, University of California - Los Angeles, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"2025090109140135000_6.1.e000648.1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3928\/23258160-20160808-04","article-title":"Baseline predictors of Vitreomacular Adhesion\/Traction resolution following an intravitreal injection of Ocriplasmin","volume":"47","author":"Jackson","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2025090109140135000_6.1.e000648.2","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1167\/iovs.17-22363","article-title":"Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole: the OASIS study","volume":"58","author":"Lescrauwaet","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109140135000_6.1.e000648.3","doi-asserted-by":"publisher","DOI":"10.3109\/02713680903308487"},{"key":"2025090109140135000_6.1.e000648.4","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00417-017-3747-1","article-title":"Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice","volume":"255","author":"Schumann","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025090109140135000_6.1.e000648.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110823"},{"key":"2025090109140135000_6.1.e000648.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307105"},{"key":"2025090109140135000_6.1.e000648.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.044"},{"key":"2025090109140135000_6.1.e000648.8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304219"},{"key":"2025090109140135000_6.1.e000648.9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/IAE.0000000000001982","article-title":"The OASIS MP-1 substudy: characterization of the effect of Ocriplasmin on microperimetry parameters","volume":"39","author":"Sadda","year":"2019","journal-title":"Retina"},{"key":"2025090109140135000_6.1.e000648.10","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.ophtha.2016.06.043","article-title":"Results of the 2-year Ocriplasmin for treatment for symptomatic Vitreomacular adhesion including macular hole (OASIS) randomized trial","volume":"123","author":"Dugel","year":"2016","journal-title":"Ophthalmology"},{"key":"2025090109140135000_6.1.e000648.11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamaophthalmol.2013.8258","article-title":"Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography","volume":"132","author":"Tibbetts","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2025090109140135000_6.1.e000648.12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/ICB.0000000000000175","article-title":"Persistent retinal changes after intravitreal ocriplasmin","volume":"10","author":"Margo","year":"2016","journal-title":"Retin Cases Brief Rep"},{"key":"2025090109140135000_6.1.e000648.13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1055\/s-0041-111807","article-title":"Transient subfoveal fluid and visual loss after Ocriplasmin","volume":"233","author":"Tschuppert","year":"2016","journal-title":"Klin Monbl Augenheilkd"},{"key":"2025090109140135000_6.1.e000648.14","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.94"},{"key":"2025090109140135000_6.1.e000648.15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IAE.0000000000001953","article-title":"Optical coherence tomography 2: diagnostic tool to study peripheral vitreoretinal pathologies","volume":"39","author":"Cereda","year":"2019","journal-title":"Retina"},{"key":"2025090109140135000_6.1.e000648.16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/IAE.0000000000000519","article-title":"Safety profile of ocriplasmin for symptomatic vitreomacular adhesion: a comprehensive analysis of premarketing and postmarketing experiences","volume":"35","author":"Hahn","year":"2015","journal-title":"Retina"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2020-000648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:14:10Z","timestamp":1756743250000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2020-000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6,21]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjophth-2020-000648"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2020-000648","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}